Home / World Marketplace / Archive by category Global Health & Biotech (Page 4)

Archive by category Global Health & Biotech

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation

Richard Francis, Teva’s President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time) TEL AVIV, Israel, Jan. 11, 2026 (Korea Bizwire) – Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will present its ongoing transformation and expected growth trajectory [...]

Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million to support Teva’s anti-IL-15 candidate TEV-‘408 TEV-‘408 is currently in Phase 1b for treatment of vitiligo and in Phase 2a for celiac disease Funding agreement supports Teva’s Pivot to Growth [...]

Attindas Hygiene Partners Expands European Position with Key Acquisition

RALEIGH, N.C., Jan. 09, 2026 (Korea Bizwire) – Attindas Hygiene Partners’ growth strategy realized an important step forward today with its acquisition of Societá Italiana Lavorazione Cellulosa (SILC S.p.A.). Attindas executed a share purchase agreement with SILC, acquiring all shares of the 53-year-old, family-owned company. SILC S.p.A. serves customers throughout Europe with high-quality, absorbent hygiene [...]

Bruder Consulting & Venture Group to become Dark Horse Consulting Regenerative Medicine

WALNUT CREEK, Calif. and NEW YORK, Jan. 09, 2026 (Korea Bizwire) – Dark Horse Consulting Group (“DHCG” or “the Group”), a leader in strategic and operational biotherapeutics consulting, is pleased to announce the acquisition of Bruder Consulting & Venture Group (“Bruder” or “BCVG”), a strategic advisory and consulting firm with a global footprint in biotech and biopharma, known for [...]

Curium’s Investigational New Drug Application Accepted by Center for Drug Evaluation in China

Curium’s Investigational New Drug (IND) application for 177Lu-PSMA-I&T, a therapeutic agent for patients with metastatic castration-resistant prostate cancer (mCRPC), has been accepted by the Centre for Drug Evaluation (CDE) and it is now under review BOSTON, Jan. 07, 2026 (Korea Bizwire) – Curium Shanghai Pharmaceuticals Co., Ltd. (科锐霖（上海）医药有限公司), has had its Investigational New Drug (IND) application [...]

Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit

Positive results from Phase 3 HERIZON-GEA-01 results support Ziihera as the HER2-targeted agent-of-choice in HER2+ first-line metastatic GEA and Ziihera plus chemotherapy to replace trastuzumab as the new standard of care, with or without tislelizumab regardless of PD-L1 status Late-breaking results to be presented at the 2026 ASCO Gastrointestinal Cancers Symposium (ASCO GI) on January [...]

Hummingbird Bioscience Announces First Patient Dosed in Phase I Clinical Trial of HMBD-501 in Advanced HER3-Expressing Solid Malignancies

HMBD-501 is a HER3-targeted ADC with a differentiated mechanism of action, engineered by Hummingbird Bioscience for optimal safety and efficacy SINGAPORE, Jan. 06, 2026 (Korea Bizwire) – Hummingbird Bioscience, a biotherapeutics company discovering and developing transformative medicines for diseases with significant unmet need, today announced that the first patient has been dosed in a Phase [...]

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference

TEL AVIV, Israel, Jan. 05, 2026 (Korea Bizwire) – Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva’s President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026. The presentation will begin at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time). To access [...]

S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody’s Ratings Agency Revises Outlook to Positive

The two updates underscore Teva’s strong execution of its Pivot to Growth strategy and commitment to financial discipline. Moody’s affirmed Teva’s B1a rating and revised Teva’s outlook to positive from stable S&P upgraded Teva to BB+ from BB, with a stable outlook TEL AVIV, Israel, Dec. 24, 2025 (Korea Bizwire) – Teva Pharmaceutical Industries Ltd. [...]

U.S. FDA approves JASCAYD® (nerandomilast) tablets for the treatment of progressive pulmonary fibrosis in adults

Not intended for UK audiences Progressive pulmonary fibrosis (PPF) is a life-threatening, progressive lung condition, causing a continuous decline in lung function.1,2 Affecting up to 100,000 people in the U.S. and up to 5.6 million worldwide, PPF is linked to an underlying clinical interstitial lung disease (ILD) diagnosis, such as autoimmune ILD or hypersensitivity pneumonitis.3,4,5 [...]